Is Replimune Group, Inc. (REPL) a Buy, Sell, or Hold?
Replimune Group, Inc.
NASDAQ:REPL
$9.87 USD
-$0.07 (-0.65%)
- Volume
- 3.3M
- Average Volume
- 6.37M
- Market Capitalization
- $828.54M
- P/E Ratio
- -2.92
- Dividend Yield
- 0.00%
- Price Target
- $14.00
- Year High
- $13.24
- Year Low
- $1.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.79
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Sushil Patel |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | REPL |
| CUSIP | 76029N106 |
| CIK | 0001737953 |
| Web | https://www.replimune.com |
| Phone | 781 222 9600 |
| Currency | USD |
| Employees | 465 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.67 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.79 |
| Quick Ratio | 4.79 |
| Cash Ratio | 3.59 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -3.07 |
| Price / Cash Flow | -2.91 |
| Price / Book | 5.51 |
Price Target and Rating
| Average Stock Price Forecast | $14.00 |
| High Stock Price Forecast | $16.00 |
| Low Stock Price Forecast | $9.00 |
| Forecast Upside/Downside | -29.50% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.38 |
| Trailing P/E Ratio | -2.92 |
| PEG Ratio | 0.49 |
| P/E Growth | 0.49 |
| Net Income | $-313.94M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -128.57% |
| Return on Assets | -94.45% |
Financials Score
| AltmanZ Score | -4.66 |
| Piotroski Score | 1.00 |
| Working Capital | 220.89M |
| Total Assets | 332.39M |
| Ebit | -314.49M |
| Market Cap | 825.37M |
| Total Liabilities | 166.23M |
Poll Results
About Replimune Group, Inc. (NASDAQ:REPL) Stock
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune syst ... em's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial
2026-06-30 10:09:50
Replimune Group, Inc. faces a pivotal FDA AdCom for RP1 after two prior rejections, with a final FDA approval decision expected August 2, 2026. RP1 demonstrated a 34% ORR and median overall survival of 32.9 months in anti-PD-1-failed melanoma, but trial design concerns persist. REPL stock has surged over 135% since April as FDA leadership changes and collaborative dialogue opened a path for BLA resubmission.
2026-06-29 08:00:00
WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update.
2026-06-26 08:00:00
WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
2026-06-01 14:06:13
Replimune stock surges after the company aligned with the FDA on plans to resubmit its BLA for RP1 plus Opdivo in advanced melanoma.
2026-05-31 08:00:00
WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2026 American Society of Clinical Oncology annual meeting.
2026-05-30 08:00:00
WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting.
Frequently Asked Questions
-
What is the current Replimune Group, Inc. (REPL) stock price?
-
Replimune Group, Inc.(NASDAQ:REPL) stock price is $9.87 in the last trading session. During the trading session, REPL stock reached the peak price of $13.24 while $1.5 was the lowest point it dropped to. The percentage change in REPL stock occurred in the recent session was --0.65% while the dollar amount for the price change in REPL stock was -$-0.07.
-
REPL's industry and sector of operation?
-
The NASDAQ listed REPL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of REPL?
-
Konstantinos Xynos | Chief Medical Officer
Sushil Patel | Chief Executive Officer & Director
Camilo Garcia | Chief Human Resource Officer
Christopher Sarchi | Chief Commercial Officer
Andrew Schwendenman | Chief Accounting Officer & Treasurer -
How many employees does REPL have?
-
Number of REPL employees currently stands at 465. REPL operates from 500 Unicorn Park Drive, Woburn, MA 01801, US.
-
Link for REPL official website?
-
Official Website of REPL is: https://www.replimune.com
-
How do I contact REPL?
-
REPL could be contacted at phone #781 222 9600 and can also be accessed through its website. REPL operates from 500 Unicorn Park Drive, Woburn, MA 01801, US.
-
How many shares of REPL are traded daily?
-
The average number of REPL shares traded daily for last 3 months was 6.37M.
-
What is the market cap of REPL currently?
-
The market value of REPL currently stands at $828.54M with its latest stock price at $9.87